齐拉西酮不同给药方法治疗精神分裂症患者的临床疗效及安全性观察

Observation of efficacy and safety of Ziprasidone administered by different methods in treatment of schizophrenia

目的:观察齐拉西酮不同给药方法治疗精神分裂症患者的疗效和安全性。方法:选取精神分裂症患者60例,随机分为缓慢加量组和快速加量组,每组各30例,观察8周。比较治疗前后两组患者的治疗疗效、不良反应(TESS量表),并对比治疗前,治疗第1周、第4周及第8周时进行PANSS评分及治疗前、治疗第4、8周糖脂代谢指标的变化情况。结果:1经8周治疗,两组患者药物疗效比较差异无统计学意义(P>0.05);2第8周快速加量组患者PANSS低于缓慢加量组(P<0.05);3两组患者治疗前后空腹血糖(FPG)、餐后2 h血糖(2 h PG)、TG及TC组内、组间比较,差异均无统计学意义(P>0.05);4快速加量组患者的不良反应发生率低于缓慢加量组。结论:齐拉西酮治疗精神分裂症缓慢加量和快速加量两种给药方法短期疗效相当,快速加量给药方法的不良反应发生率低于缓慢加量给药方法。

Objective:To observe efficacy and safety of Ziprasidone administered by different methods in treatment of schizo-phrenia. Methods:60 patients with schizophrenia were randomly divided into fast dosing group and slow dosing group with 30 cases in each group, and treated for 8 weeks. The efficacy and adverse reactions ( TESS scale) before and after the treatment of the two group were compared. The PANSS scores before the treatment and 1, 4 and 8 weeks after the treatment, and the metabolic indexes of glucose and lipid before the treatment and 4 and 8 weeks after the treatment were also compared. Results: ( 1 ) There were no significantly differences in efficacy between two groups after the 8-week treatment (P>0. 05). (2) The PANSS score was lower in slow dosing group than in fast dosing group at 8 week (P<0. 05). (3) Fasting blood glucose (FPG), 2h postprandial blood glucose (2hPG), TG and TC had no significant changes before and after the treatment (P>0. 05). (4) The adverse reaction rate in slow dosing group was higher than in fast dosing group. Conclusions:Slow dosing and fast dosing of Ziprasidone in the treatment of schizophrenia show simi-lar short period efficacy. However, the adverse reaction rate in slow dosing group is higher than in fast dosing group.